Study explores individual differences of SARS-CoV-2 infection in ACE2-expressing stem cells – News-Medical.Net

The clinical phenotype of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is remarkable for its wide range of severity among individual patients. Genetic variations are known to mediate part of these differences.

To examine these differences, researchers in a new study used human induced pluripotent stem cells (iPSCs) from different genetically diverse individuals. These cells are used to model genetic disease since they contain the donors genetic information.

The study, published as a preprint on the bioRxiv* server, uses a panel of iPSCs from over 500 individuals. The researchers preferred undifferentiated iPSCs to reduce the time required to differentiate them, especially since infection is not always reliable.

Human iPSCs are not infected by SARS-CoV-2 since they express the viral entry receptor, the angiotensin-converting enzyme 2 (ACE2) at low levels. These cells do have high levels of the coronavirus receptor CD147 and of the serine protease TMPRSS2.

In order to render them susceptible to SARS-CoV-2 infection, the iPSCs were engineered with the relevant genes, inserted by adenovirus vectors (Ad), with almost 100% efficiency. These genes encoded human ACE2 and TMPRSS2 at over-expressing levels, leading to massive infection by the virus. TMPRSS2 overexpression alone was inadequate to produce this effect.

Two days post-infection of the ACE2-positive iPSCs, cell fusion was observed, with cell death after four days, in many cases. Under transmission electron microscopy (TEM), the infected cells showed characteristic changes, including zippered endoplasmic reticulum (ER), double-membrane spherules (DMS), and viral particles near the cell membrane.

Viral particles were seen within the endoplasmic reticulum-Golgi intermediate compartment (ERGIC), along with double-membrane vesicles (DMVs. The latter is central to the synthesis of viral RNA and is absent from uninfected cells.

Thus, TEM is a useful tool to examine the lifecycle of this virus.

TEM images of infected ACE2-iPS cells (A) TEM images of infected ACE2-iPS cells. Zippered endoplasmic reticulum, double-membrane spherule (DMS) (B), and virus particles in the ERGIC (black arrows) (C) and near the cell membrane (black arrows) (D) were observed.

Gene and protein expression was assessed on day 3 post-infection in both infected and uninfected cells. This showed that infected cells had high levels of the viral genome and of ACE2, but not of undifferentiated cell markers or of innate immunity markers. The viral nucleocapsid (N) protein was also strongly expressed in the infected cells on day 2 post-infection.

RNA-seq analysis of these cells showed that in about 7% of all genes, there was a four-fold or more change in the level of expression, and none of these encoded markers of undifferentiation or innate immune markers.

Endoderm markers, except for the CER1 gene and for CD147, NRP1, and TMPRSS2 genes, known to be SARS-CoV-2-related markers, also remained unchanged. Mesoderm and ectoderm markers were also unchanged.

These results suggest that human iPS cells maintain an undifferentiated state even when SARS-CoV-2 replicates in large numbers.

In comparison to Vero cells, iPSCs proved to show stronger drug effects on SARS-CoV-2 infection, except for interferon-beta. Of the eight drugs tested, remdesivir showed maximum antiviral activity, and ivermectin showed high cytotoxicity.

Chloroquine and Favipiravir failed to suppress viral replication. The RNA-dependent RNA Polymerase (RdRp) inhibitors (Remdesivir and EIDD-2801) and TMPRSS2 inhibitors (Camostat and Nafamostat) were proved to have antiviral activity in these cells, indicating their value in drug evaluation

The researchers then infected iPSCs from eight different donors to explore differences in infection due to purely individual factors. The virus was replicated with varying efficiency among the eight donor cell lines, despite the comparable expression of ACE2 in all of them.

The virus showed greater replication capacity in male-origin cells than females, indicating the potential for sex-mediated differences in susceptibility to be replicated in these cells. Both the androgen receptor and its target TMPRSS2 gene, of which the latter is expressed at slightly higher levels in male iPSCs, may be implicated in this difference.

The viral lifecycle can be studied in these human iPSCs if the ACE2 receptor is overexpressed. The study showed the operation of sex-specific differences in the efficiency of infection and of viral replication. The inhibitory effects of drugs were also observable in this cell model.

These results suggest that by using our iPS cell panel, it will be possible to investigate the effects of race and blood type as well as gender on SARS-CoV-2 infection.

Furthermore, the identification of genetic mutations occurring at high frequency in cells that sustain infection is made possible by the use of iPSCs from a panel with documented genomic information.

While the infection efficiency varies among different donors, the fact that none of these donors had COVID-19 limits the inference that they had varying susceptibility to the disease. The study is being taken forward by using iPSCs from patients with mild and severe COVID-19, allowing findings in infected cells to be compared with the clinical presentation of the patient.

While mutations in certain innate immune genes may be associated with symptom severity, further research is required to understand how these genes function during COVID-19. This can be conveniently done in iPSCs, which allow the easy introduction of single nucleotide mutations.

It is noteworthy that the role of ACE2 overexpression has not been ruled out in the individual differences in SARS-CoV-2 infection within iPSCs from different donors. If so, another system employing ACE2-expressing somatic cells must be used to first assess the effect of the expression and mutation of ACE2 and other related genes.

Causes of individual differences, other than genetic, are not addressed by this system, including those due to advancing age and associated reductions in CD8 T cell cytotoxicity. Studies on blood specimens may help establish the cause of such variations in susceptibility and viral replication. The ACE2-positive iPSCs remain a useful platform to examine and decide on the cause of individual variations, identify high-risk groups and evaluate new drugs.

bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Original post:

Study explores individual differences of SARS-CoV-2 infection in ACE2-expressing stem cells - News-Medical.Net

Read more
Stem Cell Therapy Market Analysis, Industry Outlook, Current Trends and Forecast by 2025 – Just Positivity

The business intelligence report on Stem Cell Therapy market offers a comprehensive analysis of the top growth stimulants, prospects, restraints, and limitations that will shape the business dynamics in the coming years. Further, the report divides the industry vertical into several segments and systematically assesses them to unearth the top revenue prospects.

Stem Cell Therapy Market will exceed USD 15 billion by 2025; as per a new research report.

Allogenic stem cell therapy segment was valued around USD 3 billion in 2018 and is anticipated to expand substantially in near future. Allogenic transplant completely replaces host cells with donor cells. It also has the potential to eliminate viral reservoirs and genetic alterations. Therefore, allogenic stem cell therapies have been extensively utilized in providing treatment to patients suffering from leukemia and several other life threatening diseases. Thus, benefits offered by allogenic stem cell therapy will surge its demand, thereby propelling segment growth.

This report has keen to several extents of analysis - industry research (global industry trends) and Stem Cell Therapy market share analysis of topmost companies, along with company profiles, and which cooperatively include about the ultimate views regarding the Stem Cell Therapy market landscape, emerging and an evolutionary segments of Stem Cell Therapy market.

Request Sample Copy of this Report @

Increasing research on developing novel therapies and personalized medicines will foster stem cell therapy market growth. For instance, scientists are extensively researching on methods to regenerate healthy heart cells from placenta that can be used in patients after myocardial infarction. This discovery will help to cure patients suffering from cardiovascular diseases and reduce mortality rates. Researchers are further examining different aspects of stem cell therapy for its applications in neurological disorders. Thus, increasing R&D activities to promote developments in stem cell therapy will positively impact the industry growth.

Orthopedic segment is anticipated to witness more than 9% growth over the forecast time frame. Substantial growth is attributed to rising accidents and trauma cases across the globe. Stem cell therapy is successfully applicable in treating bone-joint injuries that include spinal and fractured bone defects, ligament tendon, femoral head and osteogenesis imperfecta. Mesenchymal stem cell therapy is preferred in curing orthopedic diseases such as arthritis and osteoporosis due to its ability to differentiate into bones and cartilage. Above mentioned factors will surge segment growth.

Rising geriatric population will positively influence the industry growth in coming years. Elderly people are susceptible to degenerative diseases such as Parkinson?s and Alzheimer?s disorders. Stem cell therapies offer several benefits over the conventional therapeutic methods that raises its preference for curing degenerative diseases. Recently developed stem cell therapies generate healthy cells by replacing the defective cells through minimally invasive techniques. Therefore, geriatric population rely on stem cell therapies that proves beneficial for the industry growth.

Major Highlights from Table of contents are listed below for quick lookup into Stem Cell Therapy Market report

Chapter 1. Competitive Landscape

Chapter 2. Company Profiles

Chapter 3. Methodology & Scope

Chapter 4. Executive Summary

Chapter 5. Stem Cell Therapy industryInsights

Request Customization on This Report @

Read the original post:

Stem Cell Therapy Market Analysis, Industry Outlook, Current Trends and Forecast by 2025 - Just Positivity

Read more
Science on the Farm for Kids | AG | – KMAland

QUESTION:What would happen if you put a DNA sample from a human into another creature?

ANSWER:If were talking about a cross between a human and a Holstein cow, well thats not going to happen. But animal-human hybrid work has been going on for a number of years in labs all around the world. Thousands of animals contain human cells or deoxyribonucleic acid DNA. Most of those are mice with a single gene sequence of human origin.

There are mice with human-like livers that allow scientists to study the effects of drugs. Some lab monkeys carry a human form of the Huntingtons disease gene that permits scientists to investigate the development of that disease. There are sheep and pigs with bits of human organs growing inside them. The goal is that the animals will grow organs that can be used by humans.

Pig-heart valves have been implanted in humans for some years now. Theres hope that pig cells can be used for diabetes treatment. Fetal-pig neurons have been implanted into the brains of people with Parkinsons disease. Pig-liver cells have been used experimentally to cleanse the blood of people with liver failure, hoping to keep them alive until a donor can be found.

Stem cells have been created by inserting human genomes into rabbit eggs. Researchers have made mice with human prostate glands. Several sheep now live with a half-human liver. DNA from humans is inserted into bacteria to recreate the insulin gene; the insulin is used for many diabetic patients nationwide.

The goal of all that recombinant DNA technology research is to save lives and to study drugs and diseases. We cant use people in gruesome but necessary experiments. In stem-cell research human cells are the therapy. Under federal U.S. Food and Drug Administration rules one must test them in animals before testing them in people.

Some recent research has been truly exciting. They are doing to brain cells what they have previously done with liver and kidney cells. There are now humanized mice with Alzheimers symptoms. Neurological disorders kill 7 million people every year.

What has been described above is not the same as whole-body cloning. Cloning is the process of creating an identical copy of an organism. Dolly, a sheep, was cloned in 1996 in Scotland; she lived for six years. A cell was taken from her biological mother, transferred into the egg of a female sheep, implanted into a surrogate mother, grew into a fetus and eventually into an identical baby copy of the original animal.

Dolly was controversial and cloning is not simple. The success rate is terrible. Dolly was born after 277 eggs were used to create 29 embryos, which produced three lambs. Only one lived.

Theres talk about bringing back extinct species by cloning dead specimens and growing them in the wombs of similar animals. The Wooly Mammoth has been extinct since 1700 B.C. but the DNA of those creatures has been preserved intact in the frozen ice of the Russian tundra. That DNA transfer as well as cloning have raised serious moral and ethical issues. Consider whether we should be tampering with Mother Nature. Risks and benefits need to be looked at. Science may be ahead of rules and regulations in that area.

At KMA, we attempt to be accurate in our reporting. If you see a typo or mistake in a story, please contact us by emailing

Larry Scheckel is the author of Seneca Seasons: A Farm Boy Remembers. He grew up on a family farm in the hill country of southwestern Wisconsin, one of nine children. His teaching career stretched to more than 38 years teaching physics and aerospace science to more than 4,000 high school students at Tomah, Wisconsin.

Continue reading here:

Science on the Farm for Kids | AG | - KMAland

Read more
How Will Global Stem Cell Banking Market React from 2021 Onwards? The Courier – The Courier

A recent Market Research Report byMarket Research Store, on Stem Cell Banking Market Overview By Trends, Size, Industry Top Manufacturers, Industry Growth Analysis & Forecast Till 2026 Flourishing data has been added to the collection to provide readers with detailed information about market developments, includes detailed market overview, seller scenario, market dimensions, as well as depth SWOT and PESTEL valuation, aside from other internationally approved market evaluation guidelines that play vital roles in growth of spreading information.

The report Stem Cell Banking Market 2020-2026, outlines and describes the key factors influencing market growth. It proposes an in-depth study of market heights (revenue), key market segment, market share, specific geographical regions, key market players and trends in vital industries. The purpose of this report is to describe the upcoming market trends and earnings forecasts in the global Stem Cell Banking market for the next five years.

We Have New Updates Of Stem Cell Banking Market In Sample Copy@

(A free sample of this report is immediately available upon request and is updated with the addition of new research).

What Benefits Does Market Research Store Research Study Is Going To Provide?

The Pre & Post Impact of COVID- 19 on Businesses.2021 Latest industry influencing trends and development scenarioTake advantage of powerful market opportunitiesImportant decisions in planning and market expansionIdentify essential Business Segments, Market proposition & Gap AnalysisHelping in allocating marketing investmentsMRS Research Methodology

Stem Cell Banking Market By Top Manufacturers (2021-2026)

Boyalife, StemCyte, Crioestaminal, Esperite, Americord, Cryo-cell, PBKM FamiCord, Beikebiotech, PacifiCord, RMS Regrow, Stemade Biotech, Krio, CCBC, Cordlife Group, Cellsafe Biotech Group, Vcanbio, Familycord, ViaCord, Cells4life, LifeCell, CBR, Cryo Stemcell

Request A Free PDF Brochure: To Get An Additional List Of Dominant Market Players Included In This Report:

Major Product Types Covered Are:

Placental Stem Cells (PSCs), Human Embryo-derived Stem Cells (HESCs), Bone Marrow-derived Stem Cells (BMSCs), Adipose Tissue-derived Stem Cells (ADSCs), Dental Pulp-derived Stem Cells (DPSCs), Other Stem Cell Sources

Major Applications of Stem Cell Banking Covered Are:

Personalized Banking Applications, Clinical Applications, Hematopoietic Disorders, Autoimmune Disorders, Other Diseases, Research Applications, Disease Treatment Studies, Life Science Research, Drug Discovery

On Some Of The Below Factors Market Player Analysis Is Based

COVID-19 Pre & Post Impact Analysis on Manufacturers profit, Revenue, and Sales.Company OverviewPrice, sales, revenue and Gross Margin AnalysisProduct portfolioRecent initiativesShare Analysis and Market Size

Lockdowns due to COVID-19 has affected economies and industries in various countries, also the businesses shutdowns and travel bans. Due to COVID-19 the decrease in the overall market growth is also affecting the Post growth of theStem Cell Banking marketowing to the shutting down of factories, lots of obstacles in the supply chain, and a downturn in the world economy.

This report presents a complete overview, growth opportunities and market shares of Stem Cell Banking market by product type, key manufacturers, application and key regions and countries. In addition, the report discusses key producers, market developments, opportunities, challenges, and factors affecting large producers and the risks facing by the whole Stem Cell Banking market. It also analyze essential emerging trends and their effect on present and future developments.

Get Free Analysis Report Of Covid-19 Impact On Stem Cell Banking Market:

Points Covered In The Report

The points discussed in the report are the vital market players that are involved in the market such as raw material suppliers, equipment suppliers, traders, end users distributors, etc.

The detailed profile of the companies is mentioned. And the capacity, production, capacity, cost, revenue, gross margin, sales volume, price, consumption, growth rate, future strategies, import, export, supply, and the technological developments that they are making are also included in the report. 12 years of data history and forecast is analyzed in this report.

The growth factors of the market are discussed where the different users of the market are described in detail.

According to specific requirements data and information by market player, by region, by type, by application, etc., and custom research can be added.

The SWOT analysis of the market within the report. The final of the report contains conclusion part where the industrial experts opinions are included.

Stem Cell Banking Market

The market research report also offers information about strategic growth market analysis, potential investment opportunities, and Potential risks that clients will follow to design business and business models and strategies. The essential data analysis in the Stem Cell Banking market report is provided in an upright way. This means that the information is represent in the form of statistics, infographics and uncomplicated graphs to make it more easier and time-saving task for the client.

The scope of Stem Cell Banking Market size reports range from broader market scenarios to comparative prices between key players, costs, and benefits of specific market segments. The numerical data is supported by statistical tools such as SWOT analysis, SCOT analysis, BCG matrix, and PESTLE analysis. The facts and figures are shown in graphical form in a clear picture.

Stem Cell Banking The report provides detailed information about the market and the strategic developments of various vital sellers. To know about the competitive landscape of the Stem Cell Banking market, an analysis of Porters five forces model is done.The study involves market attrition analysis with specific types, source types, and application segments based on market size, growth rate, and attrition.

Key strategic developments in theStem Cell Banking marketcompetitive landscape such as acquisitions & mergers, inaugurations of different products and services, partnerships & joint ventures, MoU agreements, VC & funding activities, R&D activities, and geographic expansion among other significant activities by key players of the Stem Cell Banking market are well described in the report.

Customization Service Of The Report:

(*Please let us knowif any special requirements about this report, we can provide a custom report..*)

Table Of Contents

Executive SummaryResearch MethodologyAssumptions and Acronyms UsedMarket OverviewGlobal Market Analysis and Forecast, by ApplicationsGlobal Market Analysis and Forecast, by TypesGlobal Market Analysis and Forecast, by RegionsLatin America Market Analysis and ForecastNorth America Market Analysis and ForecastAsia Pacific Market Analysis and ForecastThe Middle East & Africa Market Analysis and ForecastEurope Market Analysis and ForecastCompetition Landscape

Research Coverage:

The Stem Cell Banking market has been segmented based on offering, technology, end-use application, and end-user. It also provides a complete view of the market across four main regions: North America, Europe, APAC, and RoW.

About Us

Market Research Store is a single destination for all the industry, company and country reports. We feature large repository of latest industry reports, leading and niche company profiles, and market statistics released by reputed private publishers and public organizations. Market Research Store is the comprehensive collection of market intelligence products and services available on air. We have market research reports from number of leading publishers and update our collection daily to provide our clients with the instant online access to our database. With access to this database, our clients will be able to benefit from expert insights on global industries, products, and market trends.

See more here:

How Will Global Stem Cell Banking Market React from 2021 Onwards? The Courier - The Courier

Read more
Bok Choy: Nutrition, Calories, Benefits, Risks, and How to Eat It – Healthline

Bok choy is a variety of Chinese white cabbage that falls into the cruciferous vegetable category along with kale, Brussels sprouts, and broccoli.

Also called pak choi, its part of the Brassica genus of plants and is native to China. In fact, within China, its the most widely eaten brassica vegetable. However, people consume it worldwide (1).

You may be aware that cruciferous vegetables can be a key part of a healthy diet. However, you might be wondering what exactly bok choy has to offer.

This article discusses the health benefits and potential downsides to eating bok choy, and suggests a few ways to incorporate it into your diet.

Similar to other leafy greens and cruciferous vegetables, bok choy is full of health-promoting nutrients, including a wide array of vitamins and minerals.

One cup (70 grams) of shredded bok choy has the following nutritional profile (2):

Bok choy is an especially good source of vitamins C and K. It also contains some fiber, a critical nutrient found only in plant foods. Fiber supports digestive health and helps reduce the risk of many chronic diseases (3, 4, 5).

Bok choy contains a wide variety of vitamins and minerals. Its particularly high in vitamins C and K. It also offers some fiber, an important nutrient for overall health.

Many of the health benefits that bok choy offers have to do with its micronutrient content.

Bok choy is also rich in antioxidants, which are compounds that protect your cells from oxidative damage that can lead to inflammation and various chronic diseases. Vitamin C is one of the many antioxidants in bok choy (6, 7, 8).

Scientists have studied the cruciferous vegetable family for its potential anticancer benefits. These effects appear to come from their sulfur-containing compounds, called glucosinolates, and their breakdown products, called isothiocyanates (9).

One study found that eating bok choy at least once per week was associated with a significantly lower risk of oral, esophageal, colorectal, breast, and kidney cancers, compared with never or occasionally consuming bok choy (10).

Additionally, bok choy is a rich source of the mineral selenium, which may also have anticancer benefits.

In one analysis of studies, researchers found that high selenium exposure, indicated by levels in the blood or toenails, was related to a lower risk of cancers of the breast, lungs, esophagus, stomach, and prostate (11).

Another analysis of studies concluded that high intake of cruciferous vegetables, like bok choy, was associated with a lower risk of stomach cancer (12).

The selenium in bok choy is beneficial for properly functioning thyroid glands. These glands are located at the front base of your neck and play a critical role in metabolism and growth.

One study found that having a low level of selenium in the bloodstream was associated with thyroid conditions, such as hypothyroidism, autoimmune thyroiditis, and enlarged thyroid, also called goiter (13).

One study found that taking selenium supplements also helped manage these conditions (14).

A number of minerals in bok choy work to maintain bone health. These include calcium, phosphorus, zinc, magnesium, and vitamin K.

Zinc and iron play a role in collagen synthesis and vitamin D metabolism. Collagen is a type of protein that forms a matrix in your joints and skeletal system, helping maintain bone structure and strength (15, 16).

Studies have found that reduced levels of these minerals are associated with collagen reduction and an increased risk of osteoporosis, a disease in which bones soften and become prone to fracture (15, 16).

Bok choy contains the minerals potassium, magnesium, and calcium, which work to help naturally regulate your blood pressure (17).

Having unmanaged high blood pressure can be a risk factor for developing heart disease (18).

Bok choy is also a good source of folate and vitamin B6. Studies have found these may prevent the buildup of homocysteine. This compound can damage blood vessels and increase the risk of heart disease and stroke if it accumulates (19, 20, 21).

Bok choy is rich in vitamins, minerals, and antioxidants that may offer benefits for thyroid function and heart and bone health. They may even have anticancer properties.

While bok choy offers a number of health benefits, it may also come with downsides for some people when consumed in large amounts.

In their raw, uncooked form, cruciferous vegetables contain an enzyme called myrosinase that breaks down the glucosinolates that these vegetables also contain (22).

Some of the breakdown products of glucosinolates may inhibit your body from absorbing iodine, which is critical for thyroid function (22).

In one case study, an older woman was hospitalized in intensive care for severe hypothyroidism and related coma. She had been eating 1421 cups (1,0001,500 grams) of raw bok choy daily for several months (22).

Though this effect may seem severe, keep in mind this is a single, extreme case. This effect may really only be a concern if you eat an unusually large amount of raw cruciferous vegetables over an extended period.

One review notes that there is little research on the potential thyroid-inhibiting effect of bok choy. However, the researchers state that typical serving sizes of bok choy probably do not impair thyroid function (1).

Furthermore, cooking bok choy deactivates the enzyme myrosinase, so thyroid inhibition isnt a concern with cooked bok choy (23).

Additionally, because bok choy is a rich source of vitamin K, you may not want to consume it in larger amounts if you take blood thinning medication.

Significant changes in your vitamin K intake can interfere with the effectiveness of these medications. This is because vitamin K plays a role in blood clotting (24).

A 1-cup (70-gram) serving of loosely packed, chopped bok choy provides about 27% of your daily vitamin K needs (2).

If you are taking blood clotting medications, such as warfarin, you can ask your healthcare provider how much bok choy is safe to consume.

One case study suggests that eating bok choy raw in very large amounts may interfere with thyroid function, but this is probably not a concern with typical serving sizes. If you take blood thinning medication, you may want to watch your intake.

People often cook bok choy in stir-fries and soups, particularly in Asian cuisine.

You can consume all parts of the bok choy plant, including its white stems and green leaves.

Here are some ideas for how to prepare and eat bok choy:

There are plenty of ways to try adding bok choy to your diet.

You can consume bok choy raw, roasted, or cooked on the stovetop in a soup, stir-fry, or fried rice dish. You can incorporate bok choy into your diet in Asian dishes and many other ways.

Bok choy is a cruciferous, leafy green vegetable native to China. People often use it in Asian cuisine.

It offers a wide variety of vitamins and minerals, as well antioxidants and fiber that are good for your health. In fact, bok choy may be beneficial for heart health, bone health, and thyroid function. It may even have anticancer properties.

You may want to eat it in cooked form to reduce your intake of myrosinase, a compound that could interfere with iodine absorption. That said, this may only be an issue if you consume bok choy raw in large amounts. Eating bok choy in typical serving sizes is generally not a concern.

Boy choy is also high in vitamin K, so you may want to eat less or avoid it if you take blood thinning medications. If you are concerned about this, ask your healthcare provider for guidance.

You can use boy choy in a number of ways, such as raw in a salad, cooked in soup, or added to a stir-fry or fried rice dish.


Bok Choy: Nutrition, Calories, Benefits, Risks, and How to Eat It - Healthline

Read more
4 Health Benefits of Cranberry Juice (Plus 4 Cranberry Juice Recipes to Try) – PureWow

Native to North America, cranberries are recognized for their bright red color, tart taste and versatility. Were talking dried cranberries, cranberry sauce, frozen cranberries and, yes, cranberry juice. Youve likely heard that this tart red drink can help ward off urinary tract infections (UTIs), but there are actually a host of other health benefits of cranberry juice, from soothing an upset stomach to reducing inflammation.

Nutrition-wise, one cup of unsweetened cranberry juice contains:

Its important, when were talking about cranberry juice and its health benefits, to differentiate between unsweetened cranberry juice and cranberry juice cocktail. When youre looking for a cranberry juice thats healthy and not filled with sugar and additives, its essential to look at labels. Cranberry juice cocktail contains added sugars, like high fructose corn syrup, and are often made with only a small amount of actual cranberry juice. In the grocery store, look for labels that say made with 100 percent real juice or that are sweetened only with natural sweeteners like apple juice. Read on for everything you need to know about the health benefits of cranberry juice, plus a few cocktails and mocktails that incorporate this tasty drink.

RELATED: 6 Ways Turmeric Tea Benefits Your Health

Notably, vitamins C and E. An 8-ounce serving of cranberry juice provides 39 percent of your recommended daily allowance of vitamin C, which is important for a variety of reasons. A powerful antioxidant, vitamin C helps stop free radicals from damaging cells and DNA in your body, which could help reduce your risk of developing various ailments like cancer or heart disease. It also helps your body produce collagen and absorb iron, and it of course boosts your immune system. The same serving of cranberry juice contains about 20 percent of your recommended daily allowance of vitamin E, which is crucial for the health of your skin, blood vessels and heart.

Cranberries are high in chemicals called polyphenols that may support heart health. A 2011 study by researchers at Oklahoma State University found that cranberry juice increased the antioxidants in the blood plasma, and that people who drank cranberry juice had lower low-density lipoprotein (LDL). LDL, for reference, is known as bad cholesterol.

The compounds in cranberries that might improve heart health can also improve digestive health. A 2016 study by researchers in Iran found that these phytochemicals can prevent the bacteria H. pylori from growing and multiplying in the stomach lining. Inhibiting the production H. pylori in the stomach is thought to promote digestive health, though the researchers did note that further studies are necessary.

This humble berry might not have reached influencer status on the food pyramid, but it packs a punchand were not just talking about its sour taste. According to, cranberries are rich in antioxidants and contain compounds that boast anti-inflammatory and bacteria-blocking benefits. As such, regular consumption of raw cranberries is thought to promote urinary tract health as well as immune and digestive system health, while potentially reducing the risk of cancer, ulcers, and degenerative diseases that stem from cell damage. Of course, eating a boatload of raw cranberries doesnt promise a clean bill of health but suffice it to say, cranberries have a good rapport with the human body.

Whether youre sticking to a strictly anti-inflammatory diet or youre just looking to detox a bit, this morning drink has got you covered. Studies have shown that both ginger and cranberries can have beneficial AI properties that will help you feel your best.

Get the recipe

This large-batch cocktail combines fresh mint, cranberry juice, orange liqueur, vodka and--our favorite part--sparkling wine (learn how to pop that bottle here). Its sure to keep your guests Champagne coupes full without any fuss. Now thats how you bring good cheer.

Get the recipe


Quick, what comes to mind when you hear hot toddy? For us, its a steaming cocktail that warms us better than a cashmere sweater. This slow-cooker cranberry hot toddy is extra festive, thanks to cranberries and tangerines instead of lemon juice. We swap in rum and brandy for traditional bourbon and garnish everything with cinnamon sticks and fresh cranberries. Its practically begging to be served at your holiday party.

Get the recipe

The only thing more impressive than margaritas made with fresh lime juice? Margs made with fresh lime juice and cranberries. These stunners from Coterie member Jane Ko are a breeze to whip up (10 minutes max) and will totally impress your friends. (Quick tip: If you dont own a cocktail shaker, its totally OK to DIY by fitting the tops of two Solo cups together.)

Get the recipe

RELATED: 31 Mocktail Recipes That Go Beyond Seltzer and Fruit Juice

Read more:

4 Health Benefits of Cranberry Juice (Plus 4 Cranberry Juice Recipes to Try) - PureWow

Read more
Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic Treatment – BioSpace

NEW YORK, Feb. 26, 2021 /PRNewswire/ --Hoth Therapeutics, Inc. (NASDAQ: HOTH), abiopharmaceutical company, todayannounced it has expanded its licensing agreementfrom North Carolina State University ("NC State") to include the worldwide development and commercialization of treatments targeting mast cell derived cancers and anaphylaxis.

The application of this newly licensed indication will be developed as a novel therapy ("HT-KIT") and shares the same molecular class as the Hoth's current HT-004 drug. Both treatments are being developed by Dr. Glenn Cruse, Assistant Professor at NC State. Dr. Cruse is a leading mast cell biologist in allergic and inflammatory diseases formerly from the National Institute of Health and currently a Hoth Scientific Advisory Board member. Dr. Cruse has been developing this technology with his team at NC State since 2017 and has generated initial proof-of-concept data in a neoplastic cell line supporting the novel activity of this therapeutics.

"We are delighted to expand this strategic alliance with NC State and our Scientific Advisory Board member, Dr. Glenn Cruse," saidRobb Knie, CEO of Hoth Therapeutics. "We believe that the HT-KIT pathway is a promising novel target for combating both mast cell-derived cancers and mast cell-mediated anaphylaxis. This expanded license agreement highlights the broad potential of our diverse pipeline that is aimed at meeting critical unmet patient needs and further supports Hoth's strategy to build a sustainable therapeutics company that is patient focused."

The HT-KIT drug is designed to more specifically target the receptor tyrosine kinase KIT in mast cells, which is required for the proliferation, survival and differentiation of bone marrow-derived hematopoietic stem cells. Mutations in the KIT pathway have been associated with several human cancers, such as gastrointestinal stromal tumors and mast cell-derived cancers (mast cell leukemia and mast cell sarcoma). Based on the initial proof-of-concept success, Hoth intends to initially target mast cell neoplasms for development of HT-KIT, which is a rare, aggressive cancer with poor prognosis.

The same target, KIT, also plays a key role in mast cell-mediated anaphylaxis, a serious allergic reaction that is rapid in onset and may cause death. Anaphylaxis typically occurs after exposure to an external allergen that results in an immediate and severe immune response. Hoth also intends to pursue the anaphylaxis indication for HT-KIT in parallel to cancer treatment and HT-004 development.

About Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's pipeline development is focused to improve the quality of life for patients suffering from indications including atopic dermatitis, skin toxicities associated with cancer therapy, chronic wounds, psoriasis, asthma, acne, and pneumonia. Hoth has also entered into two different agreements to further the development of two therapeutic prospects to prevent or treat COVID-19. To learn more, please

Forward-Looking Statement

This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

Investor Contact:LR Advisors LLCEmail:investorrelations@hoththerapeutics.comwww.hoththerapeutics.comPhone: (678) 570-6791

View original content to download multimedia:

SOURCE Hoth Therapeutics, Inc.

See the original post:

Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic Treatment - BioSpace

Read more
bluebird bio Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Operational Progress – Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ:BLUE) today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2020 and shared recent operational progress.

For over ten years, bluebird bio has been pioneering gene therapies for patients with rare diseases and cancer, and our work continues with the analysis of the recent safety events identified in our HGB-206 study in patients with sickle cell disease. We have seen the transformative benefit of these therapies and are conducting a scientific and medical investigation to best inform our path forward on behalf of the patients we hope to serve with LentiGlobin, said Nick Leschly, chief bluebird. While this work is ongoing, we remain focused on the upcoming PDUFA action due date for ide-cel for multiple myeloma next month, the potential EU approval of eli-cel for CALD mid-year and the planned US filings for -thalassemia and CALD later in the year. Through these challenges, we are keeping patients at the center and were very excited to reach a major milestone of the first commercial infusion of ZYNTEGLO in Germany earlier this month.







Regulatory Outlook

Clinical Updates and Milestones


About bluebird bio, Inc.bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, were developing gene and cell therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, were working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

bluebird bio is a human company powered by human stories. Were putting our care and expertise to work across a spectrum of disorders: cerebral adrenoleukodystrophy, sickle cell disease, -thalassemia and multiple myeloma, using gene and cell therapy technologies including gene addition, and (megaTAL-enabled) gene editing.

bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland. For more information, visit

Follow bluebird bio on social media: @bluebirdbio, LinkedIn, Instagram and YouTube.

ZYNTEGLO, LentiGlobin, and bluebird bio are trademarks of bluebird bio, Inc.

Forward-Looking StatementsThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the companys financial condition, results of operations, as well as statements regarding the Companys timing and expectations regarding its investigation of the relationship of the safety events in HGB-206 to the use of lentiviral vector BB305 in LentiGlobin gene therapy for SCD, and any myeloablation regimen used in connection with treatment; the plans for regulatory submissions for beti-cel (marketed as ZYTENGLO in the European Union), eli-cel, ide-cel, and LentiGlobin for SCD, including anticipated endpoints to support regulatory submissions and timing expectations; the companys expectations regarding the potential for the suspension-based manufacturing process for lentiviral vector; the companys expectations and execution under its revised operating plan, including its cash runway; its expectations for commercialization efforts for ZYNTEGLO in Europe; and the companys expectations for the amended collaboration agreement with BMS; as well as the companys intentions regarding the timing for providing further updates on the development and commercialization of ZYNTEGLO and the companys product candidates; the timing, leadership, structure, including the division of assets among bluebird bio and Oncology Newco, and the impact of a separation; as well as the companys intention to provide further updates on the separation and the related financing strategies for bluebird bio and Oncology Newco; and the tax free nature of the separation. Any forward-looking statements are based on managements current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company may not be able to definitively determine whether the lentiviral vector BB305 used in LentiGlobin gene therapy for SCD and in beti-cel is related to the safety events in a timely manner, or at all; the risk that the lentiviral vector BB305 has caused insertional oncogenic events, including acute myeloid leukemia; the risk that insertional oncogenic events associated with lentiviral vector or additional safety events associated with myeloablation will be discovered or reported over time; the risk that we may not be able to address regulatory authorities concerns quickly or at all and may not be able to resume our HGB-206 or HGB-210 studies in a timely manner, or at all; the risk that we may not resume patient treatment with ZYNTEGLO in the commercial context in a timely manner or at all; the risk that our lentiviral vector platform across our severe genetic disease programs may be implicated, affecting the development and potential approval elivaldogene autotemcel; the risks that we may not complete the separation on the terms or timeline currently contemplated if at all, achieve the expected benefits of a separation, and a separation could harm our business, results of operations and financial condition; the risk that the transaction might not be tax-free; we may be unable to make, on a timely or cost-effective basis, the changes necessary to operate as independent companies; Oncology Newco's lack of independent operating history and the risk that its accounting and other management systems may not be prepared to meet the financial reporting and other requirements of operating as an independent public company; dedicated financial and/or strategic funding sources may not be available on favorable terms; a separation or announcement thereof may adversely impact our ability to attract or retain key personnel; a separation may adversely impact the effectiveness of development and commercialization efforts by us and our partners; our businesses may be disrupted as a result of the announcement or pendency of the separation; the COVID-19 pandemic and resulting economic conditions will have a greater impact on the companys operations and plans than anticipated; that our amended collaboration with BMS will not continue or be successful; that preliminary positive efficacy and safety results from our prior and ongoing clinical trials will not continue or be repeated in our ongoing or future clinical trials; the risk that our plans for submitting a BLA for LentiGlobin for SCD may be delayed if the FDA does not accept our comparability plans for the use of the suspension-based manufacturing process for LVV; the risk that the BLA for ide-cel is approved by the FDA in the timeline we expect, or at all; the risk of cessation or delay of any of the ongoing development activities, including clinical studies, and commercialization efforts due to delays from the COVID-19 pandemics impact on healthcare systems; the risk that the current or planned clinical trials of our product candidates will be insufficient to support regulatory submissions or marketing approval in the United States and European Union; the risk that regulatory authorities will require additional information regarding our product candidates, resulting in delay to our anticipated timelines for regulatory submissions, including our applications for marketing approval; the risk that we will encounter challenges in the commercial launch of ZYNTEGLO in the European Union, including in managing our complex supply chain for the delivery of drug product, or in obtaining sufficient coverage or reimbursement for our products; and the risk that any one or more of our product candidates, will not be successfully developed, approved or commercialized. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled Risk Factors in our most recent Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and bluebird bio undertakes no duty to update this information unless required by law.

bluebird bio, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except per share data)


For the three months endedDecember 31,

For the twelve months endedDecember 31,






Service revenue









Collaborative arrangement revenue





Royalty and other revenue





Total revenues





Operating expenses:

Research and development





Selling, general and administrative





Cost of royalty and other revenue



bluebird bio Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Operational Progress - Business Wire

Read more
Poseida Therapeutics Provides Update on Key Programs and Developments During R&D Day – PRNewswire

SAN DIEGO, Feb. 24, 2021 /PRNewswire/ --Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company plans to highlight its clinical and preclinical pipeline progress during a virtual R&D Day to be held today, February 24, 2021 beginning at 10am ET.

"Over the past year, we have made tremendous progress as we continue to validate our novel technology platforms and advance our broad and deep clinical and preclinical programs," commented Eric Ostertag, M.D., Ph.D., Chief Executive Officer. "During today's R&D Day, we will take a deep dive into Poseida's novel cell and genetic engineering platform technologies, differentiated CAR-T programs and innovative approaches to cell and gene therapy. We look forward to highlighting our progress to date, introducing a new potential pipeline product candidate, as well as several emerging discovery programs, and discussing our corporate strategy."

Specific highlights will include an early look at the ongoing P-PSMA-101 clinical trial; demonstration of the potential for single treatment cures with a completely non-viral nanoparticle-based gene therapy system; an extensive study of our Cas-CLOVER Site-Specific Gene Editing System demonstrating best-in-class gene editing specificity; and a look at our CAR-NK, and induced pluripotent stem cell, or iPSC, capabilities.

Key Program Highlights

Autologous CAR-T Update P-BCMA-101 is an autologous CAR-T product candidate in an ongoing Phase 1 dose expansion trial and Phase 2 trial in development for the treatment of relapsed/refractory multiple myeloma to treat patients with multiple myeloma. Today's discussion will include data demonstrating the importance of T stem cell memory in CAR-T. The Company intends to provide an update on this program later in 2021.

P-PSMA-101 is a solid tumor autologous CAR-T product candidate in an ongoing Phase 1 dose escalation trial in development to treat patients with metastatic castrate resistant prostate cancer, or mCRPC.Today's presentation will include a case study of a patient with mCRPC treated with P-PSMA-101 at a dose of 0.25 x 10e6 cells/kg (~20 x 10e6 total cells) who showed a marked decrease in PSA expression levels of more than 50% in the first three weeks post treatment and is continuing on trial. The patient was reported to have Grade 1 CRS in the second week which was treated to resolution. The Company intends to provide an additional update on this program later in 2021.

Allogeneic CAR-T Update (including Cas-CLOVER off-target analysis) P-BCMA-ALLO1 is the Company's first allogeneic CAR-T product candidate in development for the treatment of relapsed/refractory multiple myeloma.The Company will present updated preclinical data and ongoing IND enabling work, with an expected filing in the first half of 2021. Data utilizing Cas-CLOVER, the Company's high-precision gene editing technology to eliminate knock out TCR and B2M to address alloreactivity in P-BCMA-ALLO1, will also be presented.

P-MUC1C-ALLO1 is the Company's allogeneic CAR-T product candidate currently in preclinical development, with the potential to treat a wide range of solid tumors, including breast and ovarian cancers. The Company will share updated preclinical data demonstrating complete tumor elimination in triple negative breast and ovarian cancer models.P-MUC1C-ALLO1 will be the first clinical product to be manufactured at Poseida's pilot manufacturing facility in San Diego, with an IND filing expected by the end of 2021.

piggyBac Delivery in vivo for Liver Directed Gene Therapies P-OTC-101 is the Company's first liver-directed gene therapy program for in vivo treatment of urea cycle disease caused by congenital mutations in the OTC gene, a condition characterized by high unmet medical need. Preclinical data from ongoing IND enabling studies will be presented by Bruce Scharschmidt, M.D., an expert in OTCdeficiency and a consultant to Poseida.

Denise Sabatino, Ph.D., a recognized expert in Factor VIII therapy for Hemophilia, will present the Company's piggyBac Factor VIII program for hemophilia A, P-FVIII-101, delivered by Poseida's proprietary nanoparticle technology.Nanoparticle plus piggyBac delivery of Factor VIII demonstrates near normal levels of Factor VIII expression in juvenile mice with a single treatment in preclinical models.

Emerging Programs TCR-T: Poseida's TCR-T platform combines the Company's piggyBac DNA delivery and Cas-CLOVER gene editing technologies in order to generate effective and functional off-the-shelf TCR-T product candidates with a high percentage of highly desirable Tscm cells.The TCR-T platform could be leveraged to increase the number of potential indications in oncology and beyond, including infectious diseases and autoimmunity.

Anti-cKit CAR-T: Safer non-genotoxic conditioning regimens are potentially possible with the Company's anti-cKit CAR-T program for hematopoietic stem cell, or HSC, conditioning, which may reduce transplant morbidity and mortality, resulting in better outcomes and a greatly expanded number of potential indications. Data include results from preclinical experiments demonstrating the ability of anti-cKit CAR-T cells to deplete human stem cell grafts in NSG mice and to prolong survival in a mouse model of AML.

Genetically Modified HSCs:HSCscan be modified via the piggyBac DNA Delivery System and/or the Cas-CLOVER Site-Specific Gene Editing System. Today's presentation will show data confirming that genetically modified HSCs engraft in the bone marrow and demonstrate long-term persistence. CAR-HSC has the potential to be a highly effective CAR-T approach, as it theoretically could provide an inexhaustible supply of effector cells to eradicate tumor and can be differentiated to generate high yields of CAR-T, CAR-NK and CAR-myeloid cells.

iPSCs:Cas-CLOVER is also efficient for creating knockouts and knock-ins in induced pluripotent stem cells, or iPSCs, with very low toxicity. Data will be presented showing the greater efficiencies of Cas-CLOVER as compared to an industry standard editing platform for therapeutic knock-in using plasmid DNA.

Genetically Modified NK Cells:The Company will also present data on efficient genetic modification of NK Cells using piggyBac and Cas-CLOVER platform technologies. The Cas-CLOVER gene editing system can be used to efficiently edit NK cells, or CAR-NK cells, while piggyBac can be used to effectively deliver large therapeutic transgenes to activated or un-activated peripheral blood NK cells which maintain CAR expression, phenotype, and function. Several emerging potential CAR-NK cell product candidates will be revealed, all of which demonstrate specific killing of cancer cells.

R&D Day Webcast InformationA live webcast of the Company's R&D Day event will be available on the Investors & Media section of Poseida's website, A replay of the webcast will be available for 30 days following the presentation.

About Poseida Therapeutics, Inc.Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac DNA Modification System, Cas-CLOVER site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our wholly-owned portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics. To learn more, visit and connect with us on Twitter and LinkedIn.

Forward-Looking StatementsStatements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding the clinical data presented, the potential benefits of Poseida's technology platforms and product candidates and Poseida's plans and strategy with respect to developing its technologies and product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Poseida's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with development and regulatory approval of novel product candidates in the biopharmaceutical industry, the fact that future clinical results could be inconsistent with results observed to date and the other risks described in Poseida's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Poseida undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

SOURCE Poseida Therapeutics, Inc.

Continued here:

Poseida Therapeutics Provides Update on Key Programs and Developments During R&D Day - PRNewswire

Read more
Stem Cell Therapy Market Set to Witness Huge Growth and Competitive Outlook Anterogen Co., Ltd, Pharmicell, STEMCELL Technologies, Astellas Pharma …

This market study on Stem Cell Therapy Market covers The market study conducted in this report analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, and distributors in the industry. Also, it sheds light on the wide-ranging competitive landscape of the global Stem Cell Therapy market. It defines about the recent innovations, applications and end users of the market.The report first introduces the market basics like definitions, classifications, applications, and industry chain overview, and then industry policies and plans, product specifications, manufacturing processes, cost structures, and so on. The challenges led by the COVID-19 pandemic, leading to a decline in demand, and several initiatives taken by the government are studied in this report. The wide range of end-use applications, Heat Pumps major types, revenue, and distributors are stated. The regional analysis covers North America, Europe, APAC, Latin America, and MEA.

Stem cell therapy market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 18.66 billion by 2027 growing with a CAGR of 9.25% in the above-mentioned forecast period. The growing awareness to therapeutic potency of stem cells in disease organization will help in driving the growth of the stem cell therapy market.

Download Exclusive Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this Industry @

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market.

The key manufacturers covered in this report:

Osiris Therapeutics, Inc MEDIPOST Co., Ltd Anterogen Co., Ltd Pharmicell Co., Ltd STEMCELL Technologies Inc Astellas Pharma Inc Cellular Engineering Technologies Inc BioTime Inc Takara Bio Inc U.S. Stem Cell, Inc BrainStorm Cell Therapeutics Inc Caladrius Biosciences, Inc Athersys

Detailed Market Analysis and Insights:

The market report also covers strategic profiling of the major players in the market, all-inclusive analysis of their basic competencies, and hence keeps competitive landscape of the market in front of the client. The world class Stem Cell Therapy business report also illustrates the CAGR values for the historic years 2019, the base year 2018 and the forecast for the years 2021-2027.An international Stem Cell Therapy report identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the market for industry. For a thriving business, it is quite essential to get knowhow of consumers demands, preferences, attitudes and their changing tastes about the specific product and this report is right there to solve this purpose.

Segmentation Of Stem Cell Therapy Market:

By Technology (Cell Acquisition, Cell Production, Cryopreservation, Expansion and Sub-Culture)

By Product (Adult Stem Cells, Human Embryonic Stem Cells, Induced Pluripotent Stem Cells)

By Applications (Musculoskeletal Disorders, Wounds, Injuries, Cardiovascular Diseases, Surgeries, Gastrointestinal Diseases, Other Applications)

By End Users (Therapeutic Companies, Cell And Tissues Banks, Tools And Reagent Companies, Service Compan


The Stem Cell Therapy market report comprises of several market dynamics and estimations of the growth rate and the market value based on market dynamics and growth inducing factors. For generation of an excellent market research report, principal attributes such as highest level of spirit, practical solutions, dedicated research and analysis, innovation, talent solutions, integrated approaches, most advanced technology and commitment plays a key role. The report contains reviews about key players in the market, major collaborations, merger and acquisitions along with trending innovation and business policies.

Competitive Landscape and Stem Cell Therapy Market Share Analysis

The major players covered in the stem cell therapy market report are Osiris Therapeutics, Inc., MEDIPOST Co., Ltd., Anterogen Co., Ltd., Pharmicell Co., Ltd., STEMCELL Technologies Inc., Astellas Pharma Inc., Cellular Engineering Technologies Inc., BioTime Inc., Takara Bio Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics Inc., Caladrius Biosciences, Inc., Athersys., Cytori Therapeutics, Inc., Fate Therapeutics Inc., Pluristem Therapeutics Inc., Thermo Fisher Scientific., Vericel Corporation., ViaCyte, Inc, AbbVie, Mesoblast Ltd., Roslin Cells, Regeneus Ltd, ReNeuron Group plc, International Stem Cell Corporation, Aastrom Biosciences, Inc., Advanced Cell Technology

To receive extensive list of important regions, ask for TOC here @

Global Stem Cell Therapy Market Scope and Market Size:-

Based on type, the stem cell therapy market is segmented into allogeneic stem cell therapy and autologous stem cell therapy On the basis of technology, the stem cell therapy market is segmented into cell acquisition, cell production, cryopreservation and expansion and sub-culture On the basis of product, the stem cell therapy market is segmented into adult stem cells, human embryonic stem cells and induced pluripotent stem cells Based on application, the stem cell therapy market is segmented into musculoskeletal disorders, wounds, injuries, cardiovascular diseases, surgeries, gastrointestinal diseases and other applications

Major Highlights from Table of contents are listed below for quick lookup into Stem Cell Therapy Market report

Important Features that are under Offering and Key Highlights of the Reports:

Detailed overview of Stem Cell Therapy Market

Changing market dynamics of the industry

In-depth market segmentation by Type, Application, etc.

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape of Stem Cell Therapy Market Products

Strategies of key players and product offerings

Potential and niche segments/regions exhibiting promising growth

On the Basis of Region

The report is mainly segmented into several key regions, with sales, revenue, market share and growth rate of Stem Cell Therapy in these regions, from 2020 to 2027, covering:

U.S., Canada and Mexico in North America, Germany, France, U.K.

Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe

China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand

Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA)

Enquire Here for, Report Enquiry, Discount and Customization:

Benefits of Buying The Report:

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

More here:

Stem Cell Therapy Market Set to Witness Huge Growth and Competitive Outlook Anterogen Co., Ltd, Pharmicell, STEMCELL Technologies, Astellas Pharma ...

Read more